• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫治疗在食管胃结合部癌中的现状。

The Current Status of Immunotherapies in Esophagogastric Cancer.

机构信息

Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, Room 1035, New York, NY 10065, USA.

出版信息

Hematol Oncol Clin North Am. 2019 Apr;33(2):323-338. doi: 10.1016/j.hoc.2018.12.007.

DOI:10.1016/j.hoc.2018.12.007
PMID:30833003
Abstract

This review summarizes completed and ongoing studies evaluating the activity of immune checkpoint inhibitors in esophagogastric cancer.

摘要

这篇综述总结了评估免疫检查点抑制剂在食管胃交界癌中的活性的已完成和正在进行的研究。

相似文献

1
The Current Status of Immunotherapies in Esophagogastric Cancer.免疫治疗在食管胃结合部癌中的现状。
Hematol Oncol Clin North Am. 2019 Apr;33(2):323-338. doi: 10.1016/j.hoc.2018.12.007.
2
The Current Status of Immunotherapies in Esophagogastric Cancer.食管癌和胃癌免疫疗法的现状
Surg Oncol Clin N Am. 2017 Apr;26(2):277-292. doi: 10.1016/j.soc.2016.10.012.
3
PD-1 and PD-L1 inhibitors in oesophago-gastric cancers.PD-1 和 PD-L1 抑制剂在食管胃结合部癌中的应用。
Cancer Lett. 2020 Jan 28;469:142-150. doi: 10.1016/j.canlet.2019.10.036. Epub 2019 Oct 25.
4
Current and Future Aspects of Immunotherapy for Esophageal and Gastric Malignancies.食管癌和胃癌免疫治疗的现状与未来展望
Am Soc Clin Oncol Educ Book. 2019 Jan;39:237-247. doi: 10.1200/EDBK_236699. Epub 2019 May 17.
5
Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer.免疫检查点抑制在胃食管交界处癌中的应用
Oncol Res Treat. 2018;41(5):272-280. doi: 10.1159/000489099. Epub 2018 Apr 27.
6
Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients.多线治疗可改善晚期胃食管腺癌患者的生存状况：一项超过 500 例患者分析结果
Clin Colorectal Cancer. 2018 Sep;17(3):223-230. doi: 10.1016/j.clcc.2018.05.014. Epub 2018 Jun 8.
7
Immunotherapy for Esophageal and Gastric Cancer.食管癌和胃癌的免疫疗法
Am Soc Clin Oncol Educ Book. 2017;37:292-300. doi: 10.1200/EDBK_175231.
8
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.帕博利珠单抗治疗晚期胃及胃食管结合部腺癌。
Future Oncol. 2018 Feb;14(5):417-430. doi: 10.2217/fon-2017-0436. Epub 2017 Nov 2.
9
Advances in Immunotherapy in Esophagogastric Cancer.免疫治疗在食管胃结合部癌中的进展。
Hematol Oncol Clin North Am. 2024 Jun;38(3):599-616. doi: 10.1016/j.hoc.2024.02.002. Epub 2024 Mar 15.
10
Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma.超越 PD-L1 领域：寻找预测胃和食管腺癌免疫治疗成功的良好生物标志物。
Cancer Lett. 2019 Feb 1;442:279-286. doi: 10.1016/j.canlet.2018.11.001. Epub 2018 Nov 9.

引用本文的文献

1
Expression and functional analyses of TERF2 in esophageal carcinoma.TERF2在食管癌中的表达及功能分析
Heliyon. 2024 Sep 18;10(18):e38040. doi: 10.1016/j.heliyon.2024.e38040. eCollection 2024 Sep 30.
2
The impact of neoadjuvant immunotherapy on perioperative outcomes and survival after esophagectomy for esophageal cancer.新辅助免疫治疗对食管癌食管切除术后围手术期结局及生存的影响。
JTCVS Open. 2023 Apr 8;14:547-560. doi: 10.1016/j.xjon.2023.03.015. eCollection 2023 Jun.
3
Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials.
免疫检查点抑制剂治疗食管或胃食管交界癌的治疗相关及免疫相关不良事件：一项随机对照试验的网状Meta分析
Front Oncol. 2022 Dec 8;12:821626. doi: 10.3389/fonc.2022.821626. eCollection 2022.
4
Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications.食管癌免疫治疗抵抗：可能的机制和临床意义。
Front Immunol. 2022 Sep 2;13:975986. doi: 10.3389/fimmu.2022.975986. eCollection 2022.
5
miR-493 by regulating of c-Jun targets Wnt5a/PD-L1-inducing esophageal cancer cell development.miR-493 通过调控 c-Jun 靶向 Wnt5a/PD-L1 诱导食管癌的发展。
Thorac Cancer. 2021 May;12(10):1579-1588. doi: 10.1111/1759-7714.13950. Epub 2021 Apr 1.
6
A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909).一项关于新辅助化疗与新辅助托瑞帕利单抗联合化疗治疗局部晚期食管鳞状细胞癌的III期研究：河南省肿瘤医院胸外科肿瘤学组1909（HCHTOG1909）。
Ann Transl Med. 2021 Jan;9(1):73. doi: 10.21037/atm-20-5404.
7
Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer.食管癌同步放化疗后联合免疫治疗行食管癌切除术的安全性和可行性。
J Thorac Cardiovasc Surg. 2021 Mar;161(3):836-843.e1. doi: 10.1016/j.jtcvs.2020.11.106. Epub 2020 Dec 17.
8
Interactive Effects of PD-L1 Expression in Tumor and Immune Cells on Prognosis of Esophageal Squamous Cell Carcinoma: A One-Center Retrospective Cohort Study.肿瘤和免疫细胞中PD-L1表达对食管鳞状细胞癌预后的交互作用：一项单中心回顾性队列研究
Onco Targets Ther. 2020 Jul 3;13:6565-6572. doi: 10.2147/OTT.S258332. eCollection 2020.
9
High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer.免疫检查点抑制剂治疗非小细胞肺癌重度级别的免疫检查点抑制剂性肺炎患者的高死亡率和低治疗效果。
Thorac Cancer. 2019 Oct;10(10):2006-2012. doi: 10.1111/1759-7714.13187. Epub 2019 Sep 3.